The U.S. Food and Drug Administration (FDA) granted an Orphan Drug Designation for an investigational therapy under development by Helix 51 company BLR Bio for the treatment of scleroderma, a rare rheumatic disease that affects connective tissue and the vascular system. “The FDA’s granting of Orphan Drug Designation to BLR-200 highlights the urgent need for new and innovative therapeutic options for patients afflicted with the disease,” said Bruce Riser, PhD, CEO of BLR Bio.
< BACK TO MAIN NEWS PAGE